모더나: 두 판 사이의 차이

|순이익 = US$−474 million (2020)[

'''모더나'''(Moderna)는 미국 [[매사추세츠주]] [[케임브리지 (매사추세츠주)|케임브리지]]에 위치한 미국의 [[바이오테크놀로지]] 기업으로, [[신약 개발]], [[의약품 개발]], [[전령 RNA]](mRNA) 전용 [[백신]] 기술에 초점을 두고 있다.<ref name=BioWorld>{{웹 인용|url=http://www.bioworld.com/content/moderna-makes-entrance-40m-round-mrna-work|author=Catherine Shaffer|date=December 6, 2013|title=Moderna Makes Entrance with $40M Round for mRNA Work|publisher=BioWorld|accessdate=Dec 11, 2013|archive-date=November 16, 2020|archive-url=https://web.archive.org/web/20201116154313/https://www.bioworld.com/articles/355400-moderna-makes-entrance-with-40m-round-for-mrna-work?v=preview|url-status=live}}</ref><ref name="CNN">{{웹 인용|first1=Robert |last1=Kuznia |first2=Katie |last2=Polglase |first3=Gianluca |last3=Mezzofiore |title=In quest for vaccine, US makes 'big bet' on company with unproven technology |url=https://edition.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html |accessdate=1 May 2020 |website=CNN Investigates |date=1 May 2020 |archive-date=16 November 2020 |archive-url=https://web.archive.org/web/20201116154315/https://edition.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html |url-status=live }}</ref> [[맥길대학교]]와 [[MIT]]를 졸업한 뒤 벤쳐투자자로 활동하는 [[누바 아페얀]]이 모더나의 공동 창업자이자 이사회장이고, 동시에 이 회사의 최대주주이다. CEO는 [[스테판 방셀]]이다.

모더나의 기술 플랫폼은 합성 mRNA를 생존 중인 세포에 삽입하며 외부에서 반응이 만들어져 전통적으로 주사하는 것이 아닌, 자체 [[면역 반응]] 개발을 위해 세포를 재프로그래밍한다. RNA를 세포에 삽입할 때 나타나는 [[부작용]]으로 인해 과거에 버려졌던 새로운 기술이다.<ref name="ST">{{웹 인용| url=https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | title=Ego, ambition, and turmoil: Inside one of biotech's most secretive startups | first=Damien | last=Garade | date=13 September 2016 | accessdate=18 May 2020 | website=[[Stat (website)| Stat]] | archive-date=16 November 2020 | archive-url=https://web.archive.org/web/20201116154313/https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | url-status=live }}</ref><ref name="FT">{{뉴스 인용| url=https://www.ft.com/content/ab138504-8c2e-11e7-a352-e46f43c5825d | title=Secretive Moderna yet to convince on $5bn valuation | first=David | last=Crow | date=6 September 2017 | accessdate=18 May 2020 | newspaper=[[Financial Times]] | archive-date=3 February 2019 | archive-url=https://web.archive.org/web/20190203171135/https://www.ft.com/content/ab138504-8c2e-11e7-a352-e46f43c5825d | url-status=live }}</ref><ref name="ST1">{{웹 인용| url=https://www.statnews.com/2017/01/10/moderna-trouble-mrna/ | title=Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine | first=Damien | last=Garde | website=[[Stat (website)|Stat]] | date=10 January 2017 | accessdate=19 May 2020 | archive-date=16 November 2020 | archive-url=https://web.archive.org/web/20201116154151/https://www.statnews.com/2017/01/10/moderna-trouble-mrna/ | url-status=live }}</ref> 2020년 11월 기준으로, 인간의 이용을 위해 승인된 mRNA 약은 존재하지 않는다.<ref name="CE">{{저널 인용|last=Cross|first=Ryan|date=3 April 2020|title=Will the coronavirus help mRNA and DNA vaccines prove their worth?|url=https://cen.acs.org/pharmaceuticals/vaccines/coronavirus-help-mRNA-DNA-vaccines/98/i14|journal=[[Chemical & Engineering News]]|volume=98|issue=14|accessdate=19 May 2020|archive-date=16 November 2020|archive-url=https://web.archive.org/web/20201116154247/https://cen.acs.org/pharmaceuticals/vaccines/coronavirus-help-mRNA-DNA-vaccines/98/i14|url-status=live}}</ref><ref name="TC">{{웹 인용|last=Peccould|first=Jean|date=14 May 2020|title=Labs are experimenting with new – but unproven – methods to create a coronavirus vaccine fast|url=https://theconversation.com/labs-are-experimenting-with-new-but-unproven-methods-to-create-a-coronavirus-vaccine-fast-134319|accessdate=19 May 2020|website=[[The Conversation (website) | The Conversation]]|archive-date=16 November 2020|archive-url=https://web.archive.org/web/20201116154148/https://theconversation.com/labs-are-experimenting-with-new-but-unproven-methods-to-create-a-coronavirus-vaccine-fast-134319|url-status=live}}</ref>